Vincenzo Di Marzo to lead GW’s pre-clinical research

Leading cannabinoid scientist joins cannabis medicine specialist

Professor Vincenzo Di Marzo has agreed to direct GW Pharmaceuticals’ global pre-clinical research programme and has become research director of GW Research Ltd and GW’s Cannabinoid Research Institute at Porton Down in the UK.

Professor Di Marzo is a leading cannabinoid scientist, co-author of more than 460 peer-reviewed publications, and in 2010 was recognised as Thompson Reuters 'top scientist of the decade' for pharmacology and toxicology.

He has previously served as president of the International Cannabinoid Research Society (ICRS) and is a recipient of ICRS’s Mechoulam Award for ‘outstanding contributions to cannabinoid research’.

Professor Di Marzo is a research director at the Institute of Biomolecular Chemistry of the National Research Council (ICB-CNR) in Pozzuoli, Naples, Italy, coordinator of the Endocannabinoid Research Group in the Naples region, and an adjunct associate professor in the Department of Pharmacology and Toxicology at the Medical College of Virginia at Virginia Commonwealth University in Richmond.

In his new engagement with GW Pharmaceuticals, Professor Di Marzo will be responsible for coordinating the research efforts of GW’s global network of cannabinoid scientists. This network now extends to more than 25 academic institutions in 11 countries and involves research in a wide range of therapeutic areas, including oncology, neuroscience, metabolic disease, inflammatory disease, gastroenterology, and dermatology. The objective of this research effort is to progress a number of GW’s new cannabinoid pipeline candidates to full clinical development.

You may also like

Manufacturing

Momentum in the US cannabidiol market gains retailers' attention

Walmart and other big-name stores in talks with food and drinks makers in preparation for the day CBD-enriched products are allowed on the shelves
Ingredients

World's first prescription cannabis medicine launched in the UK

UK is the first country to grant a full regulatory authorisation for Sativex, which will be marketed to treat spasticity associated with Multiple Sclerosis
Ingredients

Safe and accurate flow measurement for pharmaceutical production

Oval Gear (OG) meters from Titan Enterprises, fitted with a Namur sensor, provide consistent, accurate measurement across a wide range of liquids, from low-viscosity solvents to more viscous pharmaceutical ingredients
Manufacturing

NorthStar and QSA Global sign multi-year partnership to secure actinium-225 supply chain

NorthStar Medical Radioisotopes and QSA Global have announced a new strategic services agreement to support commercial-scale production of actinium-225 through a closed-loop radium-226 target supply and recycling programme for targeted alpha therapies
Ingredients

Pioneering AAV approach unlocks cause of rheumatoid arthritis pain

Karolinska Institute researchers use AAV products to uncover neural mechanisms behind rheumatoid arthritis pain
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Pharma supply chains face record drug shortages as geopolitical, cyber and quality risks converge

A new Moody's report identifies four compounding risk factors driving pharmaceutical supply chain instability and warns that siloed risk management is leaving the sector dangerously exposed
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing

As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards
Subscribe now